

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Ralph Warsinsky et al) Art Unit: 1651
 U.S. Appln. No. : 10/725,156) Examiner: To be assigned
 Confirmation No. : 4786
 U.S. Filing Date : December 1, 2003
 Title of Invention : Pramipexole For The Treatment of HIV Dementia
 Docket No. : 1/1288-1-C1

Office of Initial Patent Examination's
 Filing Receipt Corrections
 703-746-9195

REQUEST FOR CORRECTION OF FILING RECEIPT


Sir/Madam:

The undersigned respectfully requests correction of the Filing Receipt for Application Number 10/725,156. The following changes are noted on the attached copy of the Official Filing Receipt.

Please correct the name of the first named applicant from "Ralph Warsinsky" to - Ralf Warsinsky - .

No fee is believed to be due. However, if it is determined that a fee is due, the Office is hereby authorized to charge Deposit Account Number 02-2955 for said fee. Triplicate copies of this document are enclosed.

Respectfully submitted,


 Alan R. Stempel
 Registration No. 28,991

Patent Department
 Boehringer Ingelheim Corp.
 900 Ridgebury Road
 P.O. Box 368
 Ridgefield, CT 06877
 Tel: (203) 798-4868
 Date: June 24, 2004



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (a) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/725,156	12/01/2003	1651	942	1/1288-1-C1		13	5

28501

BOEHRINGER INGELHEIM CORPORATION
 900 RIDGEBURY ROAD
 P. O. BOX 368
 RIDGEFIELD, CT 06877

CONFIRMATION NO. 4786

FILING RECEIPT



OC000000012101873

Date Mailed: 03/16/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ralph Warsinsky, Mainz, GERMANY;

Ralf Warsinsky

Klaus Mendla, Ingelheim, GERMANY;
 Sandra Fleissner, Ingelheim, GERMANY;
 Lothar Kussmaul, Bemstadt, GERMANY;

Assignment For Published Patent Application

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, CT;

Domestic Priority data as claimed by applicant

This application is a CON of 10/348,293 01/21/2003 ABN
 which claims benefit of 60/386,185 08/05/2002

Foreign Applications

GERMANY DE 102 03 103 01/24/2002

If Required, Foreign Filing License Granted: 03/12/2004

Projected Publication Date: 08/24/2004

Non-Publication Request: No

Early Publication Request: No

RECEIVED

MAR 28 2004

ALAN R. STEMPEL

Title

Pramipexole for the treatment of HIV dementia

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).